Axa S.A. Denali Therapeutics Inc. Transaction History
Axa S.A.
- $33.6 Billion
- Q2 2025
A detailed history of Axa S.A. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Axa S.A. holds 293,853 shares of DNLI stock, worth $5.07 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
293,853
              Previous 293,381
              
        
           0.16%
        
      
          
        Holding current value
$5.07 Million
            Previous $3.99 Million
            
        
           3.06%
        
      
          
        % of portfolio
0.01%
            Previous 0.01%
          
        Shares
	  27 transactions
	
  Others Institutions Holding DNLI
# of Institutions
251Shares Held
135MCall Options Held
148KPut Options Held
15.4K- 
    
      Black Rock Inc. New York, NY13.2MShares$227 Million0.01% of portfolio
- 
    
      Baillie Gifford & CO12MShares$206 Million0.13% of portfolio
- 
    
      Vanguard Group Inc Valley Forge, PA11.8MShares$204 Million0.0% of portfolio
- 
    
      Price T Rowe Associates Inc Baltimore, MD6.58MShares$114 Million0.01% of portfolio
- 
    
      Ubs Asset Management Americas Inc Chicago, IL6.26MShares$108 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.31B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...